research Review of Promising Off-Label Use of Deucravacitinib
Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
Search
for
Sort by
Research
150-180 / 1000+ results research Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
research Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib
Upadacitinib effectively treats psoriasiform eczema and some related conditions.
research Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report
A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.
research Janus kinase inhibitors for alopecia areata: A narrative review
Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
research Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
research Comparison of Current International Guidelines for the Management of Alopecia Areata—Comprehensive Review
International guidelines for treating alopecia areata vary, focusing on different treatment options and related health issues.
research Biomarkers of alopecia areata disease activity and response to corticosteroid treatment
Corticosteroid treatment reduces inflammation and alters hair keratins in alopecia areata.
research Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata
Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
research Ritlecitinib in severe alopecia areata: a profile of its use
Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
research Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
Blocking JAK-STAT signaling can lead to hair growth.
research Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
research Treatment of alopecia areata with JAK inhibitors: a review of the literature
JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.
research Janus Kinase Inhibitors for Alopecia Areata
JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.
research Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
research Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
research Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
research Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications
Upadacitinib effectively treats skin conditions like eczema and psoriasis and is becoming more widely used and affordable.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research El papel de los inhibidores de JAK en la alopecia areata: revisión de la literatura
JAK inhibitors help treat alopecia areata but have high recurrence after stopping.
research Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.
research Transcriptome Dynamics Reveal Stage-Specific and Melatonin-Triggered Gene Expression Patterns During The Cashmere Growth Cycle in Capra Hircus
Melatonin affects certain genes and pathways involved in cashmere goat hair growth.
research Transcriptome Dynamics Reveal Stage-specific and Melatonin-triggered Gene Expression Patterns During the Cashmere Growth Cycle in Capra Hircus
Melatonin can increase cashmere yield by altering gene expression and restarting the growth cycle early.
research Experience with oral tofacitinib in severe alopecia areata with different clinical responses
Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
research Janus kinase inhibitors for alopecia areata: a review of clinical data
JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.
research Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.
research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
research Targeting the Janus Kinase Family in Autoimmune Skin Diseases
Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.